Alendronate for the treatment of osteoporosis in men

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 3, 2008, Pages 491-498

  Olszynski, W P ^a,b,c   Davison, K S ^b,c,d  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Saskatoon Osteoporosis Centre   (Canada)

^c Canadian Multicentre Osteoporosis Study Research Group   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

Alendronate; Bone mineral density; Fraculre; Generic; Idiopathic; Men; Osteoporosis; Primary; Secondary

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; COLECALCIFEROL; CYCLOSPORIN; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; SALCATONIN; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE DENSITY; CHEMISTRY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; IDIOPATHIC DISEASE; MALE; MONOTHERAPY; OSTEOLYSIS; OSTEOPOROSIS; PHARMACODYNAMICS; RISK REDUCTION; STOMACH DISEASE; ULCER; VERTEBRA FRACTURE; CHEMICALLY INDUCED DISORDER; FRACTURE; REVIEW;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; MALE; OSTEOPOROSIS;

EID: 39049134921     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.3.491     Document Type: Article

References (69)

1. Melton LJ 3rd. The prevalence of osteoporosis: gender and racial comparison. Calcif Tissue Int 2001;69:179-81
2. Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17:505S-511S
3. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005;16(Suppl 2):S3-7
4. Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992;2:285-9
5. Melton LJ 3rd, Atkinson EJ, O'Connor MK, et al. Bone density and fiwture risk in men. J Bone Miner Res 1998;13:1915-23
6. Orwoll ES. Osteoporosis in men. Endocrinol Metab Clin North Am 1998;27:349-67
7. Lunt M, Felsenberg D, Reeve J, et al. Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study. J Bone Miner Res 1997;12:1883-94
8. Davies KM, Stegman MR, Heaney RP, Recker RFL Prevalence and severity of vertebral fracture: the Saunders County Bone Quality Study. Osteoporos Int 1996;6:160-5
9. Jones G, White C, Nguyen T, et al. Prevalent vertebral deformities: relationship to bone mineral density and spinal osteophytosis in elderly men and women. Osteoporos Int 1996;6:233-9
10. Burger H, Van Daele PI, Grashuis K, et al. Vertebral deformities and functional impairment in men and women. J Bone Miner Res 1997;12:152-7
11. O'Neill TW, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in earopean men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996;11:1010-8
12. Jackson SA, Tenenhouse A, Robertson L. Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int 2000;11:680-7
13. Myers AH, Robinson EG, Van Natta ML, et al. Hip fractures among the elderly: factors associated with in-hospital mortality. Am J Epidemiol 1991;134:1128-37
14. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82
15. Seeman E. Unresolved issues in osteoporosis in men. Rev Endocr Metab Disord 2001;2:45-64
16. Elliott JR, Gilchrist N1, Wells JE, et al. Effects of age and sex on bone density at the hip and spine in a normal Caucasian New Zealand population. NZ Med J 1990;103:33-6
17. Slosman DO, Rizzoli R, Pichard C, et al. Longitudinal measurement of regional and whole body bone mass in young healthy adults. Osteoporos Int 1994;4:185-90
18. Orwoll ES, Oviatt SK, McClung MR, et al. The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med 1990;112:29-34
19. Jones G, Nguyen T, Sambrook P, et al. Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study. BMJ 1994;309:691-5
20. Mullender MG, Tan SD, Vico I, et al. Differences in osteocyte density and bone histomorphometry between men and women and between healthy and osteoporotic subjects. Calcif Tissue Int 2005;77:291-6
21. Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995;16:87-116
22. Khosla S, Melton LJ 3rd, Atkinson EJ, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998;83:2266-74
23. Bobba R, Adachi JD. Review of the safety and efficacy of risedronate for the treatment of male osteoporosis. Clin Interv Aging 2007;2:275-82
24. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005;16:510-6
25. Finkelstein JS, Hayes A. Hunzelman JL, et al. The effects of parathyroid hormone, alendronate or both in men with osteoporosis. N Engl J Med 2003;349:1216-26
26. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparadde [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17
27. Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoparosis: results of a 1-year study. Rheumatol Int 2006;26:427-31
28. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43
29. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral firractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
30. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
31. Hochberg MC, Thompson DE, Black DM, et al. Ma of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 2005;20:971-6
32. Bone HG, Hosking D. Devogelaer JP, et al. Ten years' experience with alendrona for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99
33. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover. a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301
34. Lenart B, Neviaser A. Peterson MG, et al. Low energy femoral diaphyseal fractures associated with alendronate use. J Bone Miner Res 2007;22
35. Cranney A, Wells G, Willan A. et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23:508-16
36. Porras AG, Holland SD, Gertz BJ. Pharmacokinectics of alendronate. Clin Pharmacokinet 1999;36:315-28
37. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999;96:133-8
38. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106
39. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the trament of osteoporosis in men. N Engl J Med 2000;343:604-10
40. Ringe JD, Faber H, Dorst A. Alendronare treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 2001;86:5252-5
41. Ringe JD, Dorst A, Faber H, Ibach K. Alendronate uvatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 2004;24:110-3
42. Ho YV, Frauman AG, Thomson W, Seeman E. Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int 2000;11:98-101
43. Gonnelli S, Cepollaro C, Montagnani A, et al. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int 2003;73:133-9
44. Olszynski WP, Davison KS, Ioannidis G, et al. Effectiveness of alendronate and eddronate in the treatment of osteoporosis in men: a prospective observational study. Osteoporos Int 2006; 17:217-24
45. Sawka AM, Papaicannou A. Artache A et al. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 2005;6:39
46. Saag XG, Koehnke P. Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96:115-23
47. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87
48. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006;79:129-37
49. Cruse LM, Valeriano J, Vasey FB, Carter JD. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. J Clin Rheumatol 2006;12:221-5
50. Amin S, Lavalley MP, Simms RW, Felson DT. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002;17:1512-26
51. Adachi JD, Saag KG, Delmn PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11
52. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007;146:416-24
53. El-Agroudy AE, El-Husseini AA. El-Sayed M, et al. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int 2005;67:2039-45
54. Giannini S, D'Angelo A, Carraro G, et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 2001;16:2111-7
55. Koc M, Tuglular S, Arikan H, et al. Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant Proc 2002;34:2111-3
56. Gonnelli S, Rottoli P, Cepollaro C, et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 1997;61:382-5
57. Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials 2004;5:269-77
58. Mondy K, Powderly WG, Claxton SA, et al. Alendronate vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005;38:426-31
59. Shimon I, Eshed V, Doolman R, et al. Alendronate for osteoporosis in men with androgen-repleted hypogonadism. Osteoporos Int 2005;16:1591-6
60. Marshall JK, Rainsford KD, James C, Hunt RH. A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract. Aliment Pharmacol Ther 2000;14:1451-7
61. Lanza F, Schwartz H, Sahba B, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000;95:3112-7
62. Miller PD, Woodson G, Licata AA. et al. Rechaltenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 2000;22:1433-42
63. Adachi JD, Adami S, Miller PD, et al. Tolerability of risedronate in postmenopausal women intolerant of alendrona. Aging (Mitano) 2001;13:347-54
64. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000;160:517-25
65. Greenspan S, Field-Munves E, Tonino R, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2002;77:1044-52
66. Eisman JA, Rizzoli R, Roman-Ivorra J, et al. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2004;20:699-705
67. Cryer B, Miller P, Petruschke RA, et al. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. Aliment Pbarmacol Ther 2005;21:599-607
68. Cosman F, Wermers RA, Recknor C, et al. Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. J Bone Miner Res 2007;22
69. Epstein S. Cryer B. Rae S, et al. Disintegration/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin 2003;19:781-9